PIIND PI Industries Q4 FY25 results (Jan–Mar 2025) and concall
P I Industries reported a resilient Q4 FY25 with 3% revenue growth and 25.6% EBITDA margin, driven by strong domestic performance and new product launches. Full year FY25 saw 4% revenue growth and 8% EBITDA growth, despite challenges in Agchem exports and higher tax rates. The company is strategically transforming into a life sciences powerhouse, with significant investments in Pharma CRDMO and Biologicals, targeting substantial growth in these new verticals while maintaining a robust pipeline in Agchem.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,221 | 1,901 | 1,787 |
| EBITDA | 628 | 512 | 456 |
| Net profit | 508 | 373 | 330 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
